Novelion Therapeutics is a biopharmaceutical company. Through its subsidiary, Co. develops and commercializes two rare disease products, metreleptin and lomitapide. Metreleptin, a recombinant analog of human leptin, is marketed in the U.S. under the brand name MYALEPT (metreleptin) for injection, as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Lomitapide is marketed in the U.S. under the brand name JUXTAPID (lomitapide) capsules, as an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein apheresis where available. We show 13 historical shares outstanding datapoints in our NVLN shares outstanding history coverage, used to compute NVLN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NVLN market cap history over the course of time is important for investors
interested in comparing NVLN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NVLN versus a peer is one thing; comparing
NVLN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NVLN can fluctuate over the course of history.
With this page we aim to empower investors researching NVLN by allowing them to research the NVLN market cap history. |
Free NVLN Email Alerts:
Video: The Importance of Market Cap
